Department of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
Thoracic Surgery Department, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
Comput Math Methods Med. 2022 Aug 5;2022:3473445. doi: 10.1155/2022/3473445. eCollection 2022.
Gastric signet ring cell carcinoma (SRCC) has shown a growth growing trend worldwide, but its clinicopathological features and prognostic-related risk factors have not been systematically studied. This systematic review was devoted to this.
PubMed, Embase, Cochrane Library, and Web of Science databases were retrieved, and retrospective cohort studies comparing clinicopathological features and related risk factors in SRCC patients were included.
In SRCC patient population, males were more than females (male, OR = 1.38, 95% CI: 1.20-1.60); N3 patients were more than N0-2 patients (N0-2, OR = 3.19, 95% CI: 1.98-5.15); M1 patients were more than M0 patients (M0, OR = 3.30, 95% CI: 1.88-5.80); patients with tumor > 5 cm were more than those with tumor (≤5 cm, OR = 7.36, 95% CI: 1.33-40.60). Patients with age < 60 years (age ≥ 60 years, OR = 1.03, 95% CI: 1.01-1.05), lymphatic vessel invasion (no, OR = 1.74, 95% CI: 1.03-2.45), T2 (T1, OR = 1.17, 95% CI: 1.07-1.28) and T4 (T1, OR = 2.55, 95% CI: 2.30-2.81) stages, and N1 (N0, OR = 1.73, 95% CI: 1.08-2.38), N2 (N0, OR = 2.24, 95% CI: 1.12-3.36), and N3 (N0, OR = 3.45, 95% CI: 1.58-5.32) stages had higher hazard ratio (HR).
SRCC may occur frequently in male. Age, lymphatic vessel invasion, TN, and M stage may be risk factors for poor prognoses of SRCC patients.
胃印戒细胞癌(SRCC)在全球范围内呈增长趋势,但尚未对其临床病理特征和预后相关的危险因素进行系统研究。本系统综述即致力于此。
检索 PubMed、Embase、Cochrane 图书馆和 Web of Science 数据库,纳入比较 SRCC 患者临床病理特征和相关危险因素的回顾性队列研究。
在 SRCC 患者人群中,男性多于女性(男性,OR = 1.38,95%CI:1.20-1.60);N3 患者多于 N0-2 患者(N0-2,OR = 3.19,95%CI:1.98-5.15);M1 患者多于 M0 患者(M0,OR = 3.30,95%CI:1.88-5.80);肿瘤>5cm 的患者多于肿瘤(≤5cm,OR = 7.36,95%CI:1.33-40.60)。年龄<60 岁(年龄≥60 岁,OR = 1.03,95%CI:1.01-1.05)、淋巴管侵犯(无,OR = 1.74,95%CI:1.03-2.45)、T2(T1,OR = 1.17,95%CI:1.07-1.28)和 T4(T1,OR = 2.55,95%CI:2.30-2.81)期以及 N1(N0,OR = 1.73,95%CI:1.08-2.38)、N2(N0,OR = 2.24,95%CI:1.12-3.36)和 N3(N0,OR = 3.45,95%CI:1.58-5.32)期患者的危险比(HR)更高。
SRCC 可能多见于男性。年龄、淋巴管侵犯、TNM 分期和 M 分期可能是 SRCC 患者预后不良的危险因素。